PIP and breast carcinoma: In the study of Luo et al. (2013), the expression of the GCDFP-15 marker in primary breast cancers (invasive and in situ) was 31.6%, which was 47.2% in 30.6% of invasive tumors and in situ ductal carcinoma (DCIS) (23).